EVOK
Evoke Pharma, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$19M
5Y Perf.-96.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EVOK vs MBRX
Revenue, margins, valuation, and 5-year total return — side by side.
MBRX
Moleculin Biotech, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-99.7%
EVOK vs MBRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EVOK | MBRX |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $19M | $29M |
| Revenue (TTM) | $14M | $0.00 |
| Net Income (TTM) | $-5M | $-24M |
| Gross Margin | 97.0% | — |
| Operating Margin | -36.0% | — |
| Total Debt | $5M | $222K |
| Cash & Equiv. | $14M | $9M |
EVOK vs MBRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EVOK
MBRX
| Stock | May 20 | Dec 25 | Return |
|---|---|---|---|
| Evoke Pharma, Inc. (EVOK) | 100 | 3.1 | -96.9% |
| Moleculin Biotech, … (MBRX) | 100 | 0.3 | -99.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EVOK vs MBRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EVOK and MBRX are tied at the top with 3 categories each — the right choice depends on your priorities. Moleculin Biotech, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
EVOK
Evoke Pharma, Inc.
The Growth Play
EVOK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 97.8%, EPS growth 90.0%, 3Y rev CAGR 85.0%
- -98.5% 10Y total return vs MBRX's -99.7%
- Lower volatility, beta -0.13, Low D/E 73.3%, current ratio 1.66x
Best for: growth exposure and long-term compounding
MBRX
Moleculin Biotech, Inc.
The Quality Compounder
MBRX is the clearest fit if your priority is quality and stability.
- 0.5% margin vs EVOK's -36.2%
- Lower D/E ratio (1.5% vs 73.3%)
- 0.4% yield; 1-year raise streak; the other pay no meaningful dividend
Best for: quality and stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | EVOK | 97.8% revenue growth vs MBRX's -10.1% |
| Quality / Margins | MBRX | 0.5% margin vs EVOK's -36.2% |
| Stability / Safety | MBRX | Lower D/E ratio (1.5% vs 73.3%) |
| Dividends | MBRX | 0.4% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | EVOK | +253.7% vs MBRX's +149.2% |
| Efficiency (ROA) | EVOK | -33.4% ROA vs MBRX's -112.5%, ROIC -6.1% vs -441.5% |
EVOK vs MBRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
EVOK vs MBRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEVOKLAGGINGMBRX
MBRXMoleculin Biotech, In…
2leads
EVOKEvoke Pharma, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs MBRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MBRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MBRX5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
EVOK4/5
Risk & VolatilityBeta, volatility, and downside exposure
EVOK2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MBRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
EVOK and MBRX operate at a comparable scale, with $14M and $0 in trailing revenue.
| Metric | EVOKEvoke Pharma, Inc. | MBRXMoleculin Biotech… |
|---|---|---|
| RevenueTrailing 12 months | $14M | $0 |
| EBITDAEarnings before interest/tax | -$5M | -$25M |
| Net IncomeAfter-tax profit | -$5M | -$24M |
| Free Cash FlowCash after capex | -$3M | -$23M |
| Gross MarginGross profit ÷ Revenue | +97.0% | — |
| Operating MarginEBIT ÷ Revenue | -36.0% | — |
| Net MarginNet income ÷ Revenue | -36.2% | — |
| FCF MarginFCF ÷ Revenue | -23.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +61.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +52.1% | +134.5% |
MBRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — EVOK and MBRX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | EVOKEvoke Pharma, Inc. | MBRXMoleculin Biotech… |
|---|---|---|
| Market CapShares × price | $19M | $29M |
| Enterprise ValueMkt cap + debt − cash | $11M | $21M |
| Trailing P/EPrice ÷ TTM EPS | -3.91x | -0.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.85x | — |
| Price / BookPrice ÷ Book value/share | 2.98x | 1.97x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — EVOK and MBRX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MBRX leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
EVOK delivers a -155.4% return on equity — every $100 of shareholder capital generates $-155 in annual profit, vs $-3 for MBRX. MBRX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to EVOK's 0.73x. On the Piotroski fundamental quality scale (0–9), EVOK scores 4/9 vs MBRX's 3/9, reflecting mixed financial health.
| Metric | EVOKEvoke Pharma, Inc. | MBRXMoleculin Biotech… |
|---|---|---|
| ROE (TTM)Return on equity | -155.4% | -3.2% |
| ROA (TTM)Return on assets | -33.4% | -112.5% |
| ROICReturn on invested capital | -6.1% | -4.4% |
| ROCEReturn on capital employed | -2.3% | -187.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.73x | 0.01x |
| Net DebtTotal debt minus cash | -$8M | -$9M |
| Cash & Equiv.Liquid assets | $14M | $9M |
| Total DebtShort + long-term debt | $5M | $222,000 |
| Interest CoverageEBIT ÷ Interest expense | -9.45x | — |
MBRX leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
EVOK leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MBRX five years ago would be worth $496 today (with dividends reinvested), compared to $483 for EVOK. Over the past 12 months, EVOK leads with a +253.7% total return vs MBRX's +149.2%. The 3-year compound annual growth rate (CAGR) favors EVOK at -25.6% vs MBRX's -40.7% — a key indicator of consistent wealth creation.
| Metric | EVOKEvoke Pharma, Inc. | MBRXMoleculin Biotech… |
|---|---|---|
| YTD ReturnYear-to-date | — | -31.2% |
| 1-Year ReturnPast 12 months | +253.7% | +149.2% |
| 3-Year ReturnCumulative with dividends | -58.8% | -79.2% |
| 5-Year ReturnCumulative with dividends | -95.2% | -95.0% |
| 10-Year ReturnCumulative with dividends | -98.5% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -25.6% | -40.7% |
EVOK leads this category, winning 4 of 5 comparable metrics.
Risk & Volatility
EVOK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EVOK is the less volatile stock with a -0.13 beta — it tends to amplify market swings less than MBRX's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EVOK currently trades 100.0% from its 52-week high vs MBRX's 31.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EVOKEvoke Pharma, Inc. | MBRXMoleculin Biotech… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.13x | 1.22x |
| 52-Week HighHighest price in past year | $11.00 | $7.98 |
| 52-Week LowLowest price in past year | $2.46 | $0.25 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +31.2% |
| RSI (14)Momentum oscillator 0–100 | 85.1 | 48.5 |
| Avg Volume (50D)Average daily shares traded | 0 | 110K |
EVOK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MBRX is the only dividend payer here at 0.35% yield — a key consideration for income-focused portfolios.
| Metric | EVOKEvoke Pharma, Inc. | MBRXMoleculin Biotech… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 4 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $0.01 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MBRX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EVOK leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallEvoke Pharma, Inc. (EVOK)Leads 2 of 6 categories
Loading custom metrics...
EVOK vs MBRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EVOK or MBRX a better buy right now?
Analysts rate Moleculin Biotech, Inc.
(MBRX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EVOK or MBRX?
Over the past 5 years, Moleculin Biotech, Inc.
(MBRX) delivered a total return of -95. 0%, compared to -95. 2% for Evoke Pharma, Inc. (EVOK). Over 10 years, the gap is even starker: EVOK returned -98. 5% versus MBRX's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EVOK or MBRX?
By beta (market sensitivity over 5 years), Evoke Pharma, Inc.
(EVOK) is the lower-risk stock at -0. 13β versus Moleculin Biotech, Inc. 's 1. 22β — meaning MBRX is approximately -1029% more volatile than EVOK relative to the S&P 500. On balance sheet safety, Moleculin Biotech, Inc. (MBRX) carries a lower debt/equity ratio of 1% versus 73% for Evoke Pharma, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — EVOK or MBRX?
On earnings-per-share growth, the picture is similar: Evoke Pharma, Inc.
grew EPS 90. 0% year-over-year, compared to 82. 0% for Moleculin Biotech, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EVOK or MBRX?
Moleculin Biotech, Inc.
(MBRX) is the more profitable company, earning 0. 0% net margin versus -52. 2% for Evoke Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBRX leads at 0. 0% versus -50. 8% for EVOK. At the gross margin level — before operating expenses — EVOK leads at 96. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — EVOK or MBRX?
In this comparison, MBRX (0.
4% yield) pays a dividend. EVOK does not pay a meaningful dividend and should not be held primarily for income.
07Is EVOK or MBRX better for a retirement portfolio?
For long-horizon retirement investors, Evoke Pharma, Inc.
(EVOK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 13)). Both have compounded well over 10 years (EVOK: -98. 5%, MBRX: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EVOK and MBRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EVOK is a small-cap high-growth stock; MBRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.